Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.5%. By the end of trading, Santarus fell $0.94 (-3.9%) to $23.20 on average volume. Throughout the day, 1,606,607 shares of Santarus exchanged hands as compared to its average daily volume of 1,416,300 shares. The stock ranged in price between $23.02-$24.30 after having opened the day at $24.23 as compared to the previous trading day's close of $24.14. Other companies within the Drugs industry that declined today were:
), down 37.8%,
), down 9.1%,
), down 8.1% and
), down 7.8%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass
Santarus, Inc., a specialty biopharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. Santarus has a market cap of $1.6 billion and is part of the health care sector. Shares are up 122.3% year to date as of the close of trading on Monday. Currently there are 4 analysts that rate Santarus a buy, no analysts rate it a sell, and none rate it a hold.
TheStreet Ratings rates
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.
- You can view the full Santarus Ratings Report.
On the positive front,
), up 44.2%,
), up 32.7%,
), up 29.0% and
), up 16.5% , were all gainers within the drugs industry with
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.